Efgartigimod significantly improves Guillain-Barré syndrome disability scores and safety profile compared to IVIg
Background
Guillain-Barré syndrome (GBS) is a severe, acute autoimmune neuropathy where the body's immune system attacks its own peripheral nerves, leading to rapid-onset muscle weakness and paralysis. Current established therapeutic options, primarily intravenous immunoglobulin (IVIg) and plasma exchange, have limitations in efficacy and safety profiles for all patients. Efgartigimod, a human IgG antibody Fc fragment, functions as an FcRn antagonist, accelerating the degradation of pathogenic IgG antibodies. This mechanism offers a promising approach to modulate the autoimmune response in GBS, addressing a critical gap in targeted therapies.
Study Design
A retrospective observational study was conducted on 52 GBS patients from two hospitals between February 2024 and June 2025. Patients received either IVIg (n=20), efgartigimod (n=16), or IVIg sequential efgartigimod (ISE) (n=16). Disease severity was assessed using the GBS disability score (GBS-DS) and Inflammatory Neuropathy Cause and Treatment (INCAT) disability score at baseline, week 1, week 2, week 3, week 4, and final follow-up. The primary outcome was the proportion of good improvement, defined as a reduction of at least 2 points in the GBS-DS compared to baseline. All treatment-related adverse events were documented.
Results
Efgartigimod demonstrated superior efficacy in improving GBS disability scores. The proportion of patients achieving good improvement was significantly higher in the efgartigimod group compared to the IVIg group at both week 2 (37.5% vs. 0%, p<0.01) and the final visit (81.3% vs. 40.0%, p=0.02). Throughout the follow-up period, the proportion of patients with a GBS-DS ≤1 was consistently higher in the efgartigimod group compared to the other two treatment arms. Although not statistically significant, the mean time to reach GBS-DS ≤1 was numerically shorter in the efgartigimod group (2.6 ± 1.2 weeks) compared to IVIg (3.1 ± 1.1 weeks) and ISE (2.8 ± 1.2 weeks).
Key Findings
- Efgartigimod group showed significantly higher good improvement at week 2 (37.5% vs. 0% in IVIg, p<0.01).
- Good improvement at final visit was significantly higher with efgartigimod (81.3% vs. 40.0% in IVIg, p=0.02).
- Proportion of patients with
GBS-DS≤1 was consistently higher in the efgartigimod group. - Mean time to reach
GBS-DS≤1 was numerically shorter in efgartigimod group (2.6 ± 1.2 weeks) vs. IVIg (3.1 ± 1.1 weeks). - Incidence of treatment-related adverse events was lower in efgartigimod (18.8%) compared to IVIg (50.0%) and ISE (43.8%).
Why It Matters
This preliminary real-world data suggests that efgartigimod could offer a more effective and safer therapeutic option for Guillain-Barré syndrome patients compared to traditional IVIg therapy. The significant improvement in disability scores and a lower incidence of treatment-related adverse events highlight its potential to change clinical practice. For clinicians, this means considering efgartigimod as a primary or sequential treatment, potentially leading to faster recovery and better patient outcomes. While a specific dosing protocol isn't detailed, the observed efficacy and safety profile in a real-world setting provides strong impetus for larger, prospective studies. The practical takeaway is that efgartigimod may offer a superior risk-benefit profile for GBS patients, potentially accelerating recovery and reducing side effects.
efgartigimod
guillain-barre-syndrome
autoimmune-neuropathy
fc-receptor-inhibitor
retrospective-study
clinical-outcomes